Naloxegol-13C, d2

Naloxegol-13C, d2 (NKTR-118-13C, d2) is 13C labeled Naloxegol. Naloxegol (NKTR-118; AZ-13337019) is a μ-opioid-receptor antagonist. Naloxegol inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation[1][2].

Product Specifications

Product Name Alternative

NKTR-118-13C, d2; AZ-13337019-13C, d2

UNSPSC

12352211

Target

Isotope-Labeled Compounds; Opioid Receptor

Related Pathways

GPCR/G Protein; Neuronal Signaling; Others

Applications

Cancer-programmed cell death

Field of Research

Neurological Disease; Cancer

Smiles

O[C@]12[C@@]34C5=C(C[C@@]2([H])N(CC4)C/C=[13C]([2H])/[2H])C=CC(O)=C5O[C@@]3([H])[C@H](CC1)OCCOCCOCCOCCOCCOCCOCCOC

Molecular Formula

C33 13CH51D2NO11

Molecular Weight

654.79

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Yoon SC, et al. Naloxegol in opioid-induced constipation: a new paradigm in the treatment of a common problem. Patient Prefer Adherence. 2017 Jul 24;11:1265-1271.|[3]Garnock-Jones KP, et al. Naloxegol: a review of its use in patients with opioid-induced constipation. Drugs. 2015 Mar;75 (4) :419-25.